Digital Obesity Care Reaches Socioeconomically Diverse Patients
In a real-world cohort of over 40,000 people living with obesity, digital care engaged patients across all socioeconomic groups, including low- and middle-income populations. However, affordability emerged as the primary driver of treatment discontinuation, with economic barriers disproportionately limiting long-term access and continuity of care.
Real-World Outcomes of Tirzepatide and Semaglutide in 40,000+ Patients
Sustained Real-World Weight Loss in 40,000+ Patients
Substantial weight loss was achieved with GLP-1–based pharmacotherapy within a comprehensive digital obesity care model. Outcomes were maintained up to 24 months, with 57% of patients still in treatment, demonstrating strong long-term effectiveness in real-world care.
High-Volume Patient–Caregiver Interactions in a Fully Digital Obesity Care Model
Digital obesity care enables high levels of patient–caregiver interaction and sustained engagement in treatment, with higher retention than in other settings, potentially supporting longterm outcomes.
Across three years, messages exchanged, weight entries logged and retention in treatment was quantified for more than 50,000 patients.
Testosterone, Obesity and Men's Health: Role, Health Impact, and Treatment Options
Obesity significantly impacts men’s hormonal health — particularly testosterone — increasing risks of fatigue, weight gain, and chronic disease; understanding this connection is key to effective treatment and long-term wellbeing.
Understanding the Far-Reaching Risks of Obesity in Men: A Comprehensive Overview
Obesity in men is more than a weight issue — it’s a complex medical condition with far-reaching health risks. From heart disease and liver problems to hormonal and psychological effects, understanding these connections is key to effective prevention and management.



.webp)

.webp)




